



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/647,766 Confirmation No.: 2747
Applicant: Somers
Filed: August 25, 2003
TC/AU.: Unassigned
Examiner: Unassigned
Docket No.: 04676.105082 ATH 109 CON 6
Customer No.: 20786
Title: Compounds and Methods for the Inhibition of the Expression of VCAM-1

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmittal of Information Disclosure Statement

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of the following references are enclosed: AM, AN, AO, AP, AR, AV, AW, AY, AZ, AAC, BH, BK, BL, BM, BN, BO, BP, BQ, BR, BU, BZ, CB, CP, DB, DC, DD, DE, DG, DH, DJ, DK, DL, DM, EF, FM, FN, GA, GC, and GD. All other listed references were cited during prosecution of the parent applications U.S.S.N. 09/079,213, now issued as USP 6,147,250, and U.S.S.N. 09/370,046, now issued as USP 6,548,699. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office Action on the merits of the application, as under 37 C.F.R. §1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline I. Johnston
Reg. No. 36,174

Dated August 31, 2004
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 31, 2004.

Jennifer A. Williams

3460091_2.DOC



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879_2.DOC

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear |
|---------------------|-----------------------|----------------------|-------------------------|---|--|---|
| | | Number | Kind Code (if known) | | | |
| | AA | 3,179,701 | A | Rocklin | 04-20-1965 | |
| | AB | 3,479,407 | A | Laufer | 11-18-1969 | |
| | AC | 3,576,883 | A | Neuwirth | 04-27-1971 | |
| | AD | 3,952,064 | A | Whalley | 04-20-1976 | |
| | AE | 4,029,812 | A | Wagner | 06-14-1977 | |
| | AF | 4,076,841 | A | Wagner | 02-28-1978 | |
| | AG | 4,078,084 | A | Wagner | 03-07-1978 | |
| | AH | 4,115,590 | A | Lerner | 09-19-1978 | |
| | AI | 4,752,616 | A | Hall | 06-21-1988 | |
| | AJ | 4,755,524 | A | Mueller <i>et al.</i> | 07-05-1988 | |
| | AK | 4,954,514 | A | Kita | 09-04-1990 | |
| | AL | 4,968,710 | A | Rustad | 11-06-1990 | |
| | AM | 4,975,467 | A | Ku <i>et al.</i> | 12-04-1990 | |
| | AN | 5,043,330 | A | Nguyen <i>et al.</i> | 08-27-1991 | |
| | AO | 5,061,734 | A | Mao <i>et al.</i> | 10-29-1991 | |
| | AP | 5,066,822 | A | Rustad <i>et al.</i> | 11-19-1991 | |
| | AQ | 5,084,214 | A | Kita <i>et al.</i> | 01-28-1992 | |
| | AR | 5,112,870 | A | Mao <i>et al.</i> | 05-12-1992 | |
| | AS | 5,155,250 | A | Parker | 10-13-1992 | |
| | AT | 5,206,247 | A | Regnier | 04-27-1993 | |
| | AU | 5,262,439 | A | Parthasarathy | 11-16-1993 | |
| | AV | 5,294,724 | A | Jendralla <i>et al.</i> | 03-15-1994 | |
| | AW | 5,310,949 | A | Dufresne <i>et al.</i> | 05-10-1994 | |
| | AX | 5,380,747 | A | Medford | 01-10-1995 | |
| | AY | 5,411,741 | A | Azias | 05-02-1995 | |
| | AZ | 5,512,595 | A | Regnier <i>et al.</i> | 04-30-1996 | |
| | AAA | 5,608,095 | A | Parker | 03-04-1997 | |
| | AAB | 5,627,205 | A | Regnier <i>et al.</i> | 05-06-1997 | |
| | AAC | 5,693,337 | A | Suzuki <i>et al.</i> | 12-02-1997 | |
| | AAD | 5,739,374 | A | Janssen <i>et al.</i> | 04-14-1998 | |
| | AAE | 5,750,351 | A | Medford | 05-12-1998 | |
| | AAF | 5,773,209 | A | Medford <i>et al.</i> | 06-30-1998 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

7

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879 2.DOC

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear |
|---------------------|-----------------------|----------------------|-------------------------|---|--|---|
| | | Number | Kind Code (if known) | | | |
| | BA | 5,773,231 | A | Medford <i>et al.</i> | 06-30-1998 | |
| | BB | 5,783,596 | A | Medford <i>et al.</i> | 07-21-1998 | |
| | BC | 5,792,787 | A | Medford <i>et al.</i> | 08-11-1998 | |
| | BD | 5,807,884 | A | Medford <i>et al.</i> | 09-15-1998 | |
| | BE | 5,811,449 | A | Medford <i>et al.</i> | 09-22-1998 | |
| | BF | 5,821,260 | A | Medford <i>et al.</i> | 10-13-1998 | |
| | BG | 5,846,959 | A | Medford <i>et al.</i> | 12-08-1998 | |
| | BH | 6,037,377 | A | Anderskewitz <i>et al.</i> | 03-14-2000 | |
| | BI | 6,121,319 | A | Somers | 09-19-2000 | |
| | BJ | 6,147,250 | A | Somers | 11-14-2000 | |
| | BK | 6,323,359 | B1 | Jass | 11-27-2001 | |
| | BL | 2002-0188118 | A1 | Meng | 12-12-2002 | |
| | BM | 2002-0193446 | A1 | Meng | 12-19-2002 | |
| | BN | 2003-0064967 | A1 | Luchoomun <i>et al.</i> | 04-03-2003 | |
| | BO | 6,548,699 | B1 | Somers | 04-15-2003 | |
| | BP | 6,602,914 | B2 | Meng | 08-05-2003 | |
| | BQ | 6,617,352 | B2 | Somers | 09-09-2003 | |
| | BR | 6,670,398 | B2 | Edwards <i>et al.</i> | 12-30-2003 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|---------------------|-----------------------|-------------------------|-----------|--------------------------------------|---|--|---|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| | BS | DE | 27 16 125 | A1 | Yoshitomo Pharm. Inds. Ltd. | 10-27-1977 | | |
| | BT | EP | 0,190,682 | | G.D. Searle & Co. | 08-13-1986 | | |
| | BU | EP | 0,254,272 | A2 | Merrell Dow Pharmaceuticals Inc. | 01-27-1988 | | |
| | BV | EP | 0,292,660 | A2 | Merrell Dow Pharmaceuticals Inc. | 11-30-1988 | | |
| | BW | EP | 0,317,165 | B1 | Riker Laboratories Inc. | 05-24-1989 | | |
| | BX | EP | 0,348,203 | A1 | Shionogi Seiyaku KK | 12-27-1989 | | |
| | BY | EP | 0,405,788 | A2 | Shionogi Seiyaku KK | 01-02-1991 | | |
| | BZ | EP | 0,418,648 | A1 | Hoechst AG. | 03-27-1991 | | |
| | BAA | EP | 0,621,255 | A1 | Adir et Co. | 10-26-1994 | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879 2.DOC

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD- YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|---------------------|-----------------------|--------------------------|--------|--|---|---|----------------|
| | | Office ³ | Number | | | | |
| CA | EP | 0,763,527 | A1 | Adir et Co. | 03-19-1997 | | |
| CB | EP | 0,866,049 | A2 | Univesity of Wales (Swansea) | 09-23-1998 | | |
| CC | FR | 2,130,975 | A5 | Robert Aries | 11-10-1972 | | |
| CD | FR | 2,133,024 | A5 | Robert Aries | 11-24-1972 | | |
| CE | FR | 2,134,810 | A5 | Robert Aries | 12-08-1972 | | |
| CF | FR | 2,140,769 | A5 | Robert Aries | 01-19-1973 | | |
| CG | FR | 2,140,771 | A5 | Robert Aries | 01-19-1973 | | |
| CH | FR | 2,168,137 | A1 | Dynachim | 08-31-1973 | | |
| CI | GB | 1,136,539 | | Uniroyal Inc. | 12-11-1968 | | |
| CJ | GB | 1,148,550 | | Uniroyal Inc. | 04-16-1969 | | |
| CK | GB | 1,199,871 | A | Consolidation Coal Co. | 07-22-1970 | | |
| CL | JP | 49-075552 [74-75,552] | A | Sagami Chem. Res. Ctr., [Fujisawa], <i>Chem. Abs.</i> , AN 82(13):86196 (March 31, 1975), XP002115592 | 07-20-1974 | | |
| CM | JP | 06-312978 [94-212978] | A | Nippon Tobacco Sangyo <i>et al.</i> [Kobayashi], <i>Chem. Abs.</i> , AN 122(15): 187387 (April 10, 1995) XP002115602 | 11-08-1994 | | |
| CN | JP | 09-059258 [97-059258] | A | Ono Pharm. Co., [Toshiaki], <i>Chem. Abs.</i> , AN 126:277465 (May 26, 1997), XP002115599 and XP002115593 | 03-04-1997 | | |
| CO | JP | 73-28425 | | | 12-19-1995 | | |
| CP | WO | 93/02051 | A2 | Pfizer | 02-04-1993 | | |
| CQ | WO | 94/07869 | A1 | Zeneca; British Technology Grp. | 04-14-1994 | | |
| CR | WO | 95/09158 | A1 | Zeneca; British Technology Grp. | 04-06-1995 | | |
| CS | WO | 95/15760 | A1 | Merrell Dow Pharmaceuticals | 06-15-1995 | | |
| CT | WO | 95/17408 | A1 | Glaxo Wellcome | 06-29-1995 | | |
| CU | WO | 95/30415 | A1 | Emory University | 11-16-1995 | | |
| CV | WO | 96/12703 | A1 | G.D. Searle & Co. | 05-02-1996 | | |
| CW | WO | 97/15546 | A1 | Nippon Shinyaku Co. Ltd. | 05-01-1997 | | |
| CX | WO | 97/26258 | A1 | Janssen Pharmaceutica N.V. | 07-24-1997 | | |
| CY | WO | 97/48694 | A1 | University of Texas | 12-24-1997 | | |
| CZ | WO | 98/22418 | A1 | Hoechst Marion Roussel Inc. | 05-28-1998 | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

7

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879_2.DOC

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD- YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|---------------------|-----------------------|-------------------------|----------|--------------------------------------|---|---|---|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| | DA | WO | 98/51289 | A2 | Atherogenics | 11-19-1998 | | |
| | DB | WO | 98/51662 | A2 | Atherogenics Inc. | 11-19-1998 | | |
| | DC | WO | 99/15159 | A2 | Nova Molecular Inc. | 04-01-1999 | | |
| | DD | WO | 99/24400 | A1 | Vyrex | 05-20-1998 | | |
| | DE | WO | 00/26167 | A1 | Galderma Res. & Dev. S.N.C. | 05-11-2000 | | |
| | DF | WO | 00/26184 | A1 | Nemotel; Dr. Rudolph Eidenschink | 05-11-2000 | | |
| | DG | WO | 00/28332 | A1 | Atherogenics | 05-18-2000 | | |
| | DH | WO | 00/31053 | A1 | Janssen Pharmaceutica N.V. | 06-02-2000 | | |
| | DI | WO | 00/59509 | A1 | Novartis (CH); Novartis (AT) | 10-12-2000 | | |
| | DJ | WO | 01/70757 | A2,3 | Atherogenics | 09-27-2001 | | |
| | DK | WO | 01/79164 | A2,3 | Atherogenics | 10-25-2001 | | |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | DL | ANONYMOUS, "AtheroGenics announces positive Phase II results from CART-1 CLINICAL TRIAL for restenosis," (Press Release November 12, 2001). | |
| | DM | ANONYMOUS, "AtheroGenics: Faster than anticipated," <i>BioCentury Extra (The Bernstein Report of Biobusiness)</i> , Reprint from May 29, 2001. | |
| | DN | BARNHART, J.W., <i>et al.</i> , "Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs, <i>Pharmacochem. Libr.</i> , 1991(17):277-299 (1991). XP002095165 | |
| | DO | BARON, J.L., <i>et al.</i> , "The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between α -4-integrins and vascular cell adhesion molecule-1", <i>J. Clin. Invest.</i> 93:1700-1708 (April 1994). | |
| | DP | BROWN, <i>et al.</i> , "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis", <i>Ann. Rev. Biochem.</i> , 52:223-261 (1983). | |
| | DQ | BURKLY, L.C., <i>et al.</i> , "Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin", <i>Diabetes</i> , 43:529-534 (April 1994). | |
| | DR | CAREW, <i>et al.</i> , "Antiatherogenic effect of probucol unrelated to its hypcholesterolemic effect: Evidence that antioxidants <i>in vivo</i> can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:7725-7729 (November 1987). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

7

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879_2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| | | | |
|---------------------|--|---|--------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | ² |
| EA | COMINACINI, L., et al., <i>Free Radical Biology and Medicine</i> , 22(1/2):117-127 (1996) XP002095164. | | |
| EB | De MEGLIO, P., "New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity," <i>Il Farmaco, Ed. Sci.</i> 40(11):833-844 (1985). <i>With partial translation. Chem. Abstracts</i> , 104(5):28675, (February 3, 1986), XP 002124424. | | y |
| EC | FELDMAN, D., et al., "The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881," <i>Atherosclerosis</i> , 144:343-355 (December 28, 1998) | | |
| ED | FOLKMAN, J., et al., "Angiogenesis", <i>J. Biol. Chem.</i> , 267(16):10931-10934 (June 5, 1992). | | |
| EE | TRUEBIS, J., "A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits," <i>The American Society for Clinical Investigation, Inc.</i> , 94:392-398 (July 1994). | | |
| EF | GERSHBEIN et al., "Action of drugs and chemical agents on rat liver regeneration," <i>Drug and Chemical Toxicology</i> , 8(3):125-143 (1985). | | |
| EG | HEEG, et al., "Plasma levels of Probucol in man after single and repeated oral doses", <i>La Nouvelle Presse Medicale</i> , 9(40):2990-2994 (October 30, 1980). <i>Abstract in English</i> . | | |
| EH | IADEMARCO, M.F., et al., "Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)", <i>J. Biol. Chem.</i> 267(23):16323-16329 (August 15, 1992). | | |
| EI | KAZUYA et al., <i>J. Lipid Res.</i> , 32:197-204 (1991). | | |
| EJ | KELAREV, V.I., et al., <i>Khim. Geterotsikl. Soedin.</i> , no. 5, pages 667-673 (1995). Provided as <i>Chem. Abstracts</i> , AN 124:146082, XP002115604. | | |
| EK | KELAREV, V.I., et al., <i>Khim. Geterotsikl. Soedin.</i> , no. 4, pages 514-517 (1995). Provided as <i>Chem. Abstracts</i> AN 124(1):8690 (January 1, 1996) XP002115603 and XP002115596. | | |
| EL | KOCH, A.E., et al., "Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues", <i>Lab. Invest.</i> , 64(3):313-320 (1991). | | |
| EM | LANKIN, V.Z., et al., <i>Dokl. Akad. Nauk.</i> , 351(4):554-557 (1996), <i>Chem. Abstracts</i> , AN 127(6):75973u (1997), XP002115597. | | |
| EN | MAMEDOV, Ch.I., et al., <i>Mater. Nauchn. Konf. Aspir. Akad. Nauk Az. SSR</i> , 1:127-131 (1980), <i>Chem. Abstracts</i> , AN 94:30290c (1981), XP002115600 | | |
| EO | MAO., S.J., et al., "Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic watanabe Rabbits," <i>Journal of Medicinal Chemistry</i> , 34(1):298-302 (January 1991). | | |
| EP | MAO, S.J., et al., "Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogue (MDL29,311) That Does Not Lower serum Cholesterol," <i>Arteriosclerosis and Thrombosis</i> , 11(5):1266-1275 (September-October 1991) | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

7

Complete if Known

| | |
|----------------------|-----------------|
| Application Number | 10/647,766 |
| Filing Date | August 25, 2003 |
| First Named Inventor | Somers |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |

Attorney Docket Number **04676.105082 ATH 109 CON 6**

3563879 2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| | | | |
|---------------------|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | FA | MEDVEDEV, A.I., <i>et al.</i> , <i>Tezisy Dokl. Nauchn. Sess. Khim. Tekhnol. Org. Soedin. Sery Sernistykh Neftei</i> , 13 th , pages 123-124 (1974), <i>Chem. Abstracts</i> , AN 86(1):5066m (p. 437, 01-03-1977). XP002115601, XP00215594. | |
| | FB | MILLER, G.J., "High density lipoproteins and atherosclerosis", <i>Ann. Rev. Med.</i> , 31:97-108 (1980). | |
| | FC | MORALES-DUCRET, J., <i>et al.</i> , "α4/β1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes", <i>J. Immunol.</i> , 149(4):1424-1431 (August 15, 1992). | |
| | FD | NEUWORTH, M.B., "Synthesis and hypcholesterolemic activity of alkylidenedithio bisphenols," <i>J. Med. Chem.</i> , 13(4) 722-725 (1970), <i>Chem. Abstracts</i> AN 73:445047 (1970), XP002124423. | |
| | FE | OHKAWARA, Y., <i>et al.</i> , "In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: <i>In vivo</i> evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration", <i>Am. J. Respir. Cell. Mol. Biol.</i> , 12:4-12 (1995). | |
| | FF | OROSZ, C.G., <i>et al.</i> , "Role of the endothelial adhesion molecule VCAM in murine cardiac allograft rejection", <i>Immunol. Lett.</i> , 32:7-12 (1992). | |
| | FG | PARTHASARATHY, S., <i>et al.</i> , "Probucol inhibits oxidative modification of low density lipoprotein", <i>J. Clin. Invest.</i> , 77:641-644 (1986). | |
| | FH | PASTOR, S.D., <i>et al.</i> , <i>Phosphorus and Sulfur</i> , 37(3-4):117-123 (1988), <i>Chemical Abstracts</i> , AN 110(23):212254a (June 5, 1989), XP0021156682. | |
| | FI | PATTON, J.G., <i>et al.</i> , "Monoclonal antibodies to human plasma low-density lipoproteins. II. Evaluation for use in radioimmunoassay for apolipoprotein B in patients with coronary artery disease", <i>Clin. Chem.</i> , 29(11):1898-1903 (1983). | |
| | FJ | PILEWSKI, J.M., <i>et al.</i> , "Cell adhesion molecules in asthma: homing, activation, and airway remodeling", <i>J. Respir. Cell. Mol. Biol.</i> , 12:1-3 (1995). | |
| | FK | RABB, H.A., <i>et al.</i> , "The role of the leukocyte adhesion molecules VLA-4, LFA-1 and Mac-1 in allergic airway responses in the rat", <i>Am. J. Respir. Crit. Care Med.</i> , 149:1186-1191 (1994). | |
| | FL | RAMASAMY, S., <i>et al.</i> , "Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells," <i>Molecular Pharmacology</i> , 56(1):116-123 (April 5, 1999). | |
| | FM | RINNINGER, <i>et al.</i> , "Probucol enhances selective uptake of HDL-associated cholestryll esters in vitro by a scavenger receptor B-I-dependent mechanism", <i>Atheroschler. Throm. Vasc. Biol.</i> , 19:1325-1332 (1999). XP-008001008. | |
| | FN | ROBERTS, C.P., <i>et al.</i> , "Regulation of Monocyte Macrophage Differentiation by Antiglucocorticoids and Antioxidants," <i>American Journal of Obstetrics and Gynecology</i> , 179(2): 354-62 (August 1998). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-------------------------------|---|----|---|--------------------------|----------------------------|
| Substitute for form 1449A/PTO | | | | <i>Complete if Known</i> | |
| | | | | Application Number | 10/647,766 |
| | | | | Filing Date | August 25, 2003 |
| | | | | First Named Inventor | Somers |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 7 | of | 7 | Attorney Docket Number | 04676.105082 ATH 109 CON 6 |

3563879_2.DOC

| | | |
|--|-----------------------|---|
| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| | GA | SAWAYAMA, Y., <i>et al.</i> , "Effects of Probucol and Pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia", <i>Journal of the American College of Cardiology</i> , 39(4):610-616 (2002) |
| | GB | STEINBERG, D., <i>et al.</i> , "Modifications of low-density lipoprotein that increase its atherogenicity", <i>N. Eng. J. Med.</i> , 220(14):915-924 (1989). |
| | GC | TOMICH <i>et al.</i> , <i>Chemical Abstracts</i> , AN 127(6):75971s (1997). |
| | GD | WAGNER, Jr., <i>et al.</i> , <i>Chemical Abstracts</i> , AN 82:86189w (1975). |
| | GE | YANG, X.-D., <i>et al.</i> , "Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:10494-10498 (1993). |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.